A comparison between the effects of metformin and<i>N</i>-acetyl cysteine (NAC) on some metabolic and endocrine characteristics of women with polycystic ovary syndrome

Javanmanesh, Forough; Kashanian, Maryam; Rahimi, Maryam; Sheikhansari, Narges

doi:10.3109/09513590.2015.1115974

Cited by 23 publications

(24 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…98.5%) orally at a dose of 10 mg/Kg body weight, group-III was given the same dose of sodium arsenite with NAC at a dose of 50 mg/kg body weight (Sigma-Aldrich, Catalog number A7250, purity ≥99%) through oral route and the remaining NAC co-administered group IV was same as group III except the dose of NAC was 100 mg/kg body weight. The dose of NAC was selected which was comparatively low with respect to previous investigations [ [36] , [37] , [38] ]. Both sodium arsenite and NAC was dissolved in distilled water.…”

Section: Methodsmentioning

confidence: 99%

The consequence of NAC on sodium arsenite-induced uterine oxidative stress

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

The consequence of NAC on sodium arsenite-induced uterine oxidative stress

et al. 2018

View full text Add to dashboard Cite

show abstract

“…9 They found that Metformin improved the BMI, insulin level, and lipid levels better than NAC Alyssa M et al conducted a study to see the improvement of symptoms in patients with polycystic ovarian syndrome by Vitamin D and Calcium Supplementation. 10 They concluded that vitamin D supplementation improves insulin resistance in obese PCOS patients with vitamin D deficiency, and recommends administration of vitamin D supplementation to prevent onset of diabetes mellitus type II or IR development and progression.…”

Section: Discussionmentioning

confidence: 99%

A study of N-acetyl cysteine, metformin and vitamin D3 with calcium on clinical and metabolic profile in PCOS

Gupta

Chaurasia

Khatoon

et al. 2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Polycystic ovarian syndrome (PCOS) is characterized by the combination of hyperandrogenism, chronic anovulation and polycystic ovaries. Objective of present study was to compare the effects of N-acetyl cysteine, metformin and vitamin D3 with calcium on clinical and metabolic profile in PCOS.Methods: 66 women were randomly assigned into three equal treatment groups. Group 1 received N-acetyl cysteine, 600 mg three times a day. Group 2 metformin hydrochloride, 500 mg two times a day for 1 week, then three times a day for rest of the study and Group 3 Vit-D3 60,000 IU weekly with calcium 1500mg daily. Clinical and metabolic assessment was done at baseline and after three months of treatment.Results: After 12 weeks of treatment improvement of symptoms was seen in all the three groups, however better improvement in oligomenorrhea and hirsutism was seen in metformin group than others two groups. The clinical parameters like weight, BMI, waist hip ratio, biochemical markers of insulin resistance, fasting glucose, fasting insulin, fasting glucose/insulin ratio were significantly decreased in N-acetyl cysteine group than others two groups.Conclusions: N-acetyl cysteine had better improvement in clinical, and metabolic profile than metformin and vitamin D3 with Calcium group in PCOS patients. It can be used as a substitute for insulin reducing medications in treatment of PCOS patients, considering its limited adverse effects.

show abstract

“…The benefit of glutathione or NAC in cardiometabolic diseases is less clear, but an RCT showed that NAC inhibits platelet-monocyte conjunction in type 2 DM patients, suggesting its benefit in reducing athero-thrombotic risks in these patients 141 . NAC also appeared to be efficacious in improving metabolic abnormalities in women with polycystic ovarian syndrome, with effects comparable to metformin 142 .…”

Section: Drug Enrichment Analysesmentioning

confidence: 95%

Differential associations of various depression-related phenotypes with cardiometabolic risks: Identification of shared genetic factors and implications for drug repositioning

Wong

Chau

et al. 2017

Preprint

View full text Add to dashboard Cite

Depression and cardiometabolic diseases, such as coronary artery disease (CAD) and type 2 diabetes (DM), are commonly considered as risk factors to each other. However, little is known about the mechanism underlying the relationship between depression and cardiometabolic traits. Using a polygenic risk score approach, we investigated the genetic overlap of major depressive disorder (MDD) with various cardiometabolic traits based on summary statistics from large-scale meta-analyses of genome-wide association studies (GWAS). GWAS results for MDD were taken from MDD-CONVERGE which represents a relatively homogenous sample of severe depression. We also identified shared genetic variants and inferred the enriched pathways. In addition, we looked for drugs over-represented among the top shared genes, with an aim to finding repositioning opportunities for both kinds of disorders.We found significant polygenic sharing between MDD and cardiometabolic traits, including positive associations with CAD, fat percentage, LDL, triglyceride, body mass index (BMI), waist-hip ratio (WHR) and WHR adjusted for BMI, and an inverse association with HDL. We also observed a modest association of MDD with DM but no significant associations with other glycemic traits or leptin. Some of the shared pathways include lipoprotein metabolism, neurotrophin and oxytocin pathways. Using a gene-set analysis approach, we revealed drugs that may be repositioned for both types of disorders, many of which are supported by previous studies, such as statins, bupropion, verapamil and s-adenosylmethionine. Our study highlights shared genetic bases of MDD with cardiometabolic traits, and implicates the potential of repurposing drugs for comorbidities based on overlapping genetic factors.

show abstract

A comparison between the effects of metformin andN-acetyl cysteine (NAC) on some metabolic and endocrine characteristics of women with polycystic ovary syndrome

Abstract: NAC can improve lipid profile and fasting blood sugar (FBS) and fasting blood insulin better than metformin.

Cited by 23 publications

References 25 publications

The consequence of NAC on sodium arsenite-induced uterine oxidative stress

The consequence of NAC on sodium arsenite-induced uterine oxidative stress

A study of N-acetyl cysteine, metformin and vitamin D3 with calcium on clinical and metabolic profile in PCOS

Differential associations of various depression-related phenotypes with cardiometabolic risks: Identification of shared genetic factors and implications for drug repositioning

Contact Info

Product

Resources

About